Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes Read more about Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition Read more about Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition
Agios Reports Business Highlights and Third Quarter 2023 Financial Results Read more about Agios Reports Business Highlights and Third Quarter 2023 Financial Results
Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023 Read more about Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023
Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023 Read more about Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023
Agios Reports Business Highlights and Second Quarter 2023 Financial Results Read more about Agios Reports Business Highlights and Second Quarter 2023 Financial Results
Agios Announces Exclusive Worldwide License Agreement with Alnylam for Novel siRNA for the Potential Treatment of Polycythemia Vera Read more about Agios Announces Exclusive Worldwide License Agreement with Alnylam for Novel siRNA for the Potential Treatment of Polycythemia Vera
Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023 Read more about Agios to Webcast Conference Call of Second Quarter 2023 Financial Results on Aug. 3, 2023
Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response Read more about Agios Announces Positive Results from Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease with Both Mitapivat Dose Arms Achieving Statistically Significant Hemoglobin Response
Jeffrey Capello Chair of the Audit Committee Jeffrey Capello Director Financial Expert Independent Director